



COVID-19 vaccination status as of 0:00 today (cumulative since 26 February 2021)

	Total	City							
		Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan	Sejong
New (1st dose)	158,581	27,074	7,832	6,800	6,559	4,854	4,684	2,196	752
New (1st dose)	19,613	2,479	888	497	926	861	284	519	166
Total (1st)	2,195,492	344,869	135,113	90,987	110,681	75,480	60,628	40,941	10,976
Total (2nd)	98,767	18,380	5,848	3,943	10,665	2,854	4,320	3,866	1,162
	Total	Province							
		Gyeonggi	Gangwon	Chung-buk	Chung-nam	Jeon-buk	Jeon-nam	Gyeong-buk	Gyeong-nam
New (1st dose)	33,828	4,840	5,271	6,794	8,209	10,541	11,790	14,841	1,716
New (1st dose)	2,418	1,901	1,495	1,354	1,572	1,534	399	1,812	508
Total (1st)	461,883	82,511	83,449	113,193	107,815	130,782	146,456	171,390	28,338
Total (2nd)	14,555	4,888	5,550	4,082	3,950	3,595	2,933	5,111	3,065

※ Figures subject to correction recording update

Adverse events following COVID-19 vaccination reported as of 0:00 today (cumulative since 26 February 2021)

		Vaccinated (cumulative)	Total	%	General ¹⁾	Anaphylaxis suspected ²⁾	Severe suspected ³⁾	Deaths
Total	New	2,294,259	321	0.58	308	6	4	3
	Total		13,332		13,095	138	43	56
AstraZeneca	New	1,277,785	224	0.93	217	3	3	1
	Total		11,909		11,727	113	31	38
Pfizer	New	1,016,474	97	0.14	91	3	1	2
	Total		1,423		1,368	25	12	18

¹⁾ Mild cases such as headache, fever, nausea, vomiting, etc.

²⁾ Anaphylactoid reaction and anaphylactic shock suspected cases reported by healthcare institutions; Anaphylactoid reaction refers to occurrence of symptoms such as shortness of breath, rashes, etc. within 2 hours of vaccination and differs from anaphylaxis

³⁾ Includes convulsion and other nervous system response and ICU admitted cases

※ Based on the patient's condition at the time of initial report (general, anaphylaxis suspected, severe suspected, death)

※ Cases reported as suspected cases of AEFI; causal association not yet determined; investigation for assessment of causal association to take place for deaths or anaphylaxis cases



KDCA

Korea Disease Control and
Prevention Agency

Updates on COVID-19 in Republic of Korea

24 April 2021

Confirmed cases by gender and age group

		New cases (%)		Total cases (%)		Incidence rate* (per 100,000)
Total		785	(100)	118,243	(100)	228.06
Sex	Male	405	(51.59)	58,843	(49.76)	227.52
	Female	380	(48.41)	59,400	(50.24)	228.60
Age	80 or above	19	(2.42)	5,207	(4.40)	274.16
	70-79	45	(5.73)	8,574	(7.25)	237.70
	60-69	99	(12.61)	18,196	(15.39)	286.81
	50-59	143	(18.22)	21,909	(18.53)	252.79
	40-49	112	(14.27)	17,484	(14.79)	208.41
	30-39	104	(13.25)	15,900	(13.45)	225.69
	20-29	155	(19.75)	17,609	(14.89)	258.71
	10-19	76	(9.68)	8,268	(6.99)	167.35
0-9	32	(4.08)	5,096	(4.31)	122.84	

* Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

※ Figures subject to correction based on findings from epidemiological investigations

Deaths and severe/critical patients by gender and age group

		New deaths (%)	Total deaths (%)	Case fatality rate (%)	Severe/critical (%)
Total		1 (100)	1,812 (100)	1.53	136 (100)
Sex	Male	1 (100.00)	903 (49.83)	1.53	87 (64.0)
	Female	0 (0.00)	909 (50.17)	1.53	49 (36.0)
Age	80 or above	0 (0.00)	994 (54.86)	19.09	36 (26.5)
	70-79	1 (100.00)	520 (28.70)	6.06	41 (30.1)
	60-69	0 (0.00)	212 (11.70)	1.17	41 (30.1)
	50-59	0 (0.00)	62 (3.42)	0.28	14 (10.3)
	40-49	0 (0.00)	14 (0.77)	0.08	3 (2.2)
	30-39	0 (0.00)	7 (0.39)	0.04	0 (0.0)
	20-29	0 (0.00)	3 (0.17)	0.02	1 (0.7)
	10-19	0 (0.00)	0 (0.00)	0.00	0 (0.0)
0-9	0 (0.00)	0 (0.00)	0.00	0 (0.0)	

* Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100

※ Figures subject to correction based on findings from epidemiological investigations

AGE DISTRIBUTION OF SEVERE/CRITICAL CASES

	4.11.	4.12.	4.13.	4.14.	4.15.	4.16.	4.17.	4.18.	4.19.	4.20.	4.21.	4.22.	4.23.	4.24.
Total	105	103	101	100	99	111	108	102	99	109	116	125	127	136

* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)